3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Gastrointestinal Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
5
S 1 (combination)
4
Irinotecan
4
pembrolizumab
3
IFL protocol
3
Fluorouracil
3
Bevacizumab
3
amminedichloro(2-methylpyridine)platinum(II)
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
MLN 8237
2
Leucovorin
2
Gemcitabine
2
Folfox protocol
2
Fecal Microbiota Transplantation
2
Drug Therapy
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
CGX1321
2
ulixertinib
1
tivozanib
1
titanium silicide
1
tislelizumab
1
sodium thiosulfate
1
sacituzumab govitecan
1
remune
1
plecanatide
1
phosphatidyltransferase, Clostridium butyricum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastrointestinal Neoplasms
×
LB100
×
Clear all
NCT06012734
2024-08-30
CoLBAt
The Netherlands Cancer Institute
Phase 1
Recruiting
37 enrolled